Contact Us

Johnson Johnson Cypher Stent
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date the device was implanted:

Is the device still implanted?

What medical condition prompted the use of the device?

Please describe any problems or injuries caused by the product:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Johnson Johnson Cypher Stent

Johnson & Johnson Cypher Stent Side Effects Lawsuits | Side Effects: Heart Attacks, Strokes, Deaths, Blood Clotting, Thrombosis | Inhibits Overgrowth, Inhibits Protective Coating

Facebook Twitter Stumble AddThis Social Bookmark Button Pin It Email to Friend Print Page

Johnson Johnson Cypher Stent Side Effects May Result In Heart Attack Lawsuits

Johnson Johnson Cypher Stent | Lawsuits, Lawyers | Side Effects: Heart Attacks, Strokes, Deaths, Blood Clotting, Thrombosis | Inhibits Overgrowth, Inhibits Protective Coating

Blood clotting, or thrombosis, associated with drug coated heart stents such as Johnson & Johnson's Cypher Stent, is four to five times more likely than with regular metal stents, according to a Cleveland Clinic study released November 29, 2006.  Patients with drug-eluting stents should contact Parker & Waichman, LLP today to learn about the available legal remedies.  Call 1-800-YOURLAWYER (1-800-968-7529) for a free stent case review.  Late thrombosis associated with stents following angioplasty can lead to heart attacks, stroke and death.  The Cypher stent was approved by the FDA in April 2003 and emits the drug Sirolimus, which is intended to solve the restenosis (reclosure) problem by inhibiting the overgrowth of the endothelial cells in the blood vessels. Some health care professionals believe that Sirolimus inhibits the creation of a protective coating that grows in the vessel around the stent to protect against clots.

Earlier Stent Warnings

The FDA approved the Cypher Stent in April 2003 for angioplasty procedures to open clogged coronary arteries. In most cases, a stent is left permanently in the artery to keep the vessel open after angioplasty. The Cypher stent is designed to slowly release a drug which helps to reduce the rate of re-blockage that occurs. The FDA warned that Johnson & Johnson's newest heart device, the drug coated Cypher Stent, has been linked to hundreds of cases of blood clots and said the device has been linked to more than 60 deaths. This warning was the second warning sent to doctors since the launch of the Cypher stent in April 2003. The FDA said that Johnson & Johnson's drug-coated stent, a tiny wire mesh device used to prop open surgically cleared arteries and deliver medicine to keep them open, resulted in more than 290 cases of blood clots among patients 30 days after receiving the device. The FDA also said that the Cypher stent was associated with other serious injuries that required medical or surgical intervention, including more than 50 reports, including some deaths, that J&J considers to be possible hypersensitivity allergic reactions. The symptoms include pain, rash, respiratory alterations, hives, itching, fever and blood pressure changes.

Angioplasty

Each year, 800,000 angioplasty procedures are performed in the United States to open clogged coronary arteries. In approximately 15%-30% of patients, the artery becomes clogged again (a condition called restenosis) within a year, and it must be treated again with a procedure such as angioplasty or bypass surgery.

Legal Help For Victims Affected By Johnson Johnson Cypher Stent

If you or a loved one suffered injuries from a Johnson & Johnson Cypher stent, please fill out the form at the right for a free case evaluation by a qualified defective medical device attorney.  To speak with someone immediately, call 1-800-YOURLAWYER (1-800-968-7529).

Tags:  
Johnson Johnson Cypher StentRSS Feed

Efficacy of heart stents called into question

Mar 27, 2007 | Financial Times
A seven-year US study has called into question whether doctors are overusing heart stents, the blockbuster tiny wire mesh tubes used to prop open narrowing coronary arteries. The results of the study, called Courage, added more uncertainty to a stent market that recently has been thrown into flux over questions of safety, appropriate usage and new competition. This flux was also highlighted by a 7 per cent fall in the share price of Boston Scientific, a leading US stent maker, because new...

Angioplasty no better than drugs, study says

Mar 27, 2007 | Boston Globe
A large and long-awaited study finds that angioplasty works no better than medication at preventing heart attacks or death, a finding that could slow the growth of one of medicine's most common cardiac interventions. The research comes on the heels of a growing debate over whether some patients are getting unnecessary angioplasty, a procedure that involves using a tiny balloon and metal scaffolds called stents to prop open clogged arteries. Angioplasty is recommended for those with fully...

Study: Heart Stents Often Not Worth the Risk or Cost

Mar 27, 2007 | NewsInferno.com
A highly anticipated new study has called into question the long-term effectiveness of stents in the treatment of stable coronary artery disease. Researchers have determined that the use of drug therapy (including blood-pressure and cholesterol drugs) is just as effective in preventing heart attacks or death when compared to a combination of drug therapy and stent implantation. The study results were shared this week at the American College of Cardiology’s (ACC) annual Scientific Session...

Heart Stents No Better Than Treating Stable Heart Patients With Medication, Study Shows

Mar 26, 2007 | Washington Post
The study of more than 2,000 patients found that those who underwent the expensive procedure, known as angioplasty, in non-emergency situations were no less likely to suffer a heart attack or die than those who only took aspirin and other medicines to thin their blood and lower blood pressure and cholesterol, along with adopting life style changes. The study is the first large, well-designed comparison of angioplasty to non-surgical care for patients who are not actually having heart attack or...

Heart stent makers brace for new heart study

Mar 26, 2007 | AP
Wall Street analysts and many doctors expect another potential setback for makers of stents when results of a blockbuster study Tuesday will answer whether an artery-opening procedure plus drugs is better than medication alone for lower-risk heart patients with chest pain. It's the first big study to directly compare angioplasty procedures with drug therapy alone as a way to prevent heart attacks and deaths in non-emergency cases. If the research reaches the conclusion many analysts and...

More Johnson Johnson Cypher Stent News

Parker Waichman Accolades And Reviews Law Dragon Best Lawyers Find Us On Avvo Protected by Copyscape Web Copyright Protection Software php-5 VendorsBay Inc